Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma 2Sarcoma, Endometrial Stromal 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 23Paclitaxel 14Cyclophosphamide 13Carboplatin 12Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 9fludarabine 8Nivolumab 7Leucovorin 7Gemcitabine 7Fluorouracil 7Doxorubicin 7aldesleukin 6Oxaliplatin 6Cisplatin 6liposomal doxorubicin 5Topotecan 5Taxes 5Irinotecan 5Interleukin-2 5olaparib 4atezolizumab 4Hyperthermic Intraperitoneal Chemotherapy 4Drug Therapy 4seribantumab 3fludarabine phosphate 3durvalumab 3dostarlimab 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × trebananib × Gynecologic × Clear all
NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Amgen

Phase 1 Completed
103 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡